Neurocrine Biosciences (NBIX) Operating Income (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Operating Income of $151.5 million for Q2 2026, up 4.05% year-over-year from $145.6 million in Q2 2025, and down 21.66% on a QoQ basis from $193.4 million in Q1 2026.
Neurocrine Biosciences (NBIX) Operating Income (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Operating Income for 17 years, with the latest figure at $151.5 million in Q2 2026.
- Operating Income for Q2 2026 came in at $151.5 million, up 4.05% year-over-year; the trailing twelve-month figure through Jun 2026 was $794.8 million (up 60.57% YoY), and the FY2025 annual result was $619.1 million, up 8.52% from the prior year.
- Operating Income eased to $151.5 million in Q2 2026, from $193.4 million in the prior quarter.
- Over five years, Operating Income peaked at $239.0 million in Q3 2025 and troughed at -$114.2 million in Q1 2023.
- A 5-year average of $113.0 million and a median of $141.6 million in 2023 frame the typical range for Operating Income.
- The widest annual swing landed in 2023, when Operating Income slumped 3783.87%; it then jumped 719.49% in 2026.
- A 5-year view of Operating Income shows it stood at $103.4 million in 2022, then soared by 45.36% to $150.3 million in 2023, then fell by 5.52% to $142.0 million in 2024, then soared by 48.52% to $210.9 million in 2025, then declined by 28.17% to $151.5 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were $151.5 million in Q2 2026, $193.4 million in Q1 2026, and $210.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.63 Bn | 42.66 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -231.00 Mn |
| 3 | Zoetis | 31.60 Bn | 29.93 Bn | 1.05 Bn | 837.00 Mn |
| 4 | Takeda Pharmaceutical | 28.74 Bn | 22.95 Bn | 5.10 Bn | 1.26 Bn |
| 5 | United Therapeutics | 22.36 Bn | 19.70 Bn | 683.80 Mn | 330.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 6.30 Mn |
| 7 | Neurocrine Biosciences | 15.68 Bn | 15.29 Bn | 935.80 Mn | 151.50 Mn |
| 8 | Elanco Animal Health | 12.03 Bn | 11.50 Bn | 798.00 Mn | 248.00 Mn |
| 9 | Dr Reddys Laboratories | 10.08 Bn | 9.91 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.62 Bn | 397.90 Mn | 18.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.50 Mn |
| Mar 31, 2026 | 193.40 Mn |
| Dec 31, 2025 | 210.90 Mn |
| Sep 30, 2025 | 239.00 Mn |
| Jun 30, 2025 | 145.60 Mn |
| Mar 31, 2025 | 23.60 Mn |
| Dec 31, 2024 | 142.00 Mn |
| Sep 30, 2024 | 183.80 Mn |
| Jun 30, 2024 | 145.40 Mn |
| Mar 31, 2024 | 99.30 Mn |
| Dec 31, 2023 | 150.30 Mn |
| Sep 30, 2023 | 141.20 Mn |
| Jun 30, 2023 | 73.60 Mn |
| Mar 31, 2023 | -114.20 Mn |
| Dec 31, 2022 | 103.40 Mn |
| Sep 30, 2022 | 87.80 Mn |
| Jun 30, 2022 | 54.70 Mn |
| Mar 31, 2022 | 3.10 Mn |
| Dec 31, 2021 | -36.30 Mn |
| Sep 30, 2021 | 44.50 Mn |